News
While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...
A study finds that adjunctive use of GLP-1 receptor agonists before and after undergoing bariatric surgery produces greater ...
Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...
More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...
Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in ...
16h
News-Medical.Net on MSNMuscle loss from GLP-1 drugs could undermine long-term healthPopular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in ...
A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...
GLP-1 drugs came out in 2005 as a Type 2 diabetes treatment. But in recent years their popularity for weight loss -- and the ...
11h
HealthDay on MSNDementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DMFor older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl ...
More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results